Core Insights - Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the PVRI 2026 congress, highlighting the Phase 3 PALM-PAH study design and Phase 2b study results in pulmonary arterial hypertension (PAH) [1] Group 1: Presentation Details - The presentations will include the Phase 3 PALM-PAH study design and an encore of the topline results from the Phase 2b study of TPIP in PAH [1] - A new Functional Respiratory Imaging analysis from the Phase 2b study and data on the pulmonary vasodilatory effect of TPIP in rat models will also be presented [1] - Specific presentation details include moderated poster discussions scheduled for January 30 and 31, 2026, covering various aspects of TPIP research [1] Group 2: About TPIP - TPIP is a dry powder formulation of treprostinil palmitil, designed for once-daily administration in patients with PAH and other pulmonary disorders [1] - The investigational drug has not yet received approval for any indication [1] - The Phase 2b study involved 102 adult participants across 44 sites, focusing on the efficacy, safety, and pharmacokinetics of TPIP [1] Group 3: About PAH - PAH is a serious and progressive disease characterized by high blood pressure in the pulmonary arteries, affecting approximately 35,000 patients in the U.S., 40,000 in the EU5, and 15,000 in Japan [1] - Common symptoms include shortness of breath, chest pain, dizziness, fatigue, and weakness, with untreated PAH often leading to debilitating and fatal outcomes [1] Group 4: About Insmed - Insmed is a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases [1] - The company has a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [2] - Insmed has been recognized as a top employer in the biopharmaceutical industry, emphasizing its commitment to employee satisfaction and innovation [2]

Summit Therapeutics (NASDAQ:SMMT) is one of the best large cap stocks under $100 with huge upside potential. On January 14, H.C. Wainwright analyst Mitchell Kapoor reaffirmed his optimistic outlook on Summit Therapeutics (NASDAQ:SMMT). He assigned a Buy rating to the stock with a $40 price target, resulting in an upside of nearly 143%. Copyright: dolgachov / 123RF Stock Photo Kapoor’s rating comes at the back of the company’s submission of Biologics License Application (BLA), relating to ivonescimab cl ...

Group 1 - Oppenheimer upgraded Relay Therapeutics Inc. (RLAY) to Outperform from Perform, resulting in a significant increase in the stock price since the upgrade on the 26th [1] - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Group 2 - The analyst emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns but requires careful scrutiny [1]

Core Insights - Halozyme Therapeutics has raised its revenue estimates for 2025 and provided updated financial guidance for 2026, reflecting strong growth in its core ENHANZE business and recent acquisitions [1] Financial Estimates for 2025 - Total revenue is estimated to be between $1,385 million and $1,400 million, representing a year-over-year growth of 36% to 38% [1] - Royalty revenue is projected to be between $865 million and $870 million, with a year-over-year growth of 51% to 52% [1] Financial Guidance for 2026 - Total revenue guidance has been increased to a range of $1,710 million to $1,810 million, indicating a year-over-year growth of 23% to 30% [1] - Royalty revenue guidance has been raised to between $1,130 million and $1,170 million, reflecting a growth of 30% to 35% compared to 2025 [1] - Adjusted EBITDA is expected to be between $1,125 million and $1,205 million [1] - Non-GAAP diluted EPS is projected to be between $7.75 and $8.25 [1] Strategic Acquisitions - The company acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, totaling up to $400 million [1] - Surf Bio's hyperconcentration technology aims to enable high concentrations of therapeutics for subcutaneous delivery, enhancing patient experience [1] Business Development and Partnerships - In 2025, Halozyme signed three new ENHANZE collaboration and licensing agreements, along with one new auto-injector commercial licensing agreement and two development agreements [1] - The company anticipates having 15 partner programs in development by the end of 2026, further expanding its drug delivery portfolio [1]

Table of Contents As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292633 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 EIKON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 2836 84-2807586 (Primary Standard Industrial Classification Code Number) 230 Harriet ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company focused on developing treatments for serious diseases such as cancer, inflammatory, immunologic, cardiovascular, and fibrotic diseases. With a market cap of $111.2 billion, its strong oncology portfolio includes blockbuster drug Opdivo and other drugs like Revlimid, Pomalyst, Sprycel, Yervoy, and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. Shares of this ...

Core Viewpoint - The announcement contains information classified as inside information under the Market Abuse Regulation, indicating its significance for market participants [1] Group 1 - The company asserts that the information is relevant to UK domestic law as per the European Union (Withdrawal) Act 2018 [1]

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Low Risk Stocks for a Retirement Stock Portfolio. Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy Janux Therapeutics said on January 22 that it has partnered with Bristol-Myers Squibb Company (NYSE:BMY) to develop a new cancer treatment, according to Reuters. The announcement was well received by the market, with Janux shares jumping more than 12% in premarket trading. The therapy is aimed at solid tumors, canc ...

商报记者孟佳俊 杭州生态圈：全链协同，精准破局 生物医药产业是创新驱动的长链条产业，杭州生物医药的"加速跑"，离不开全链条要素的协同共振。研 讨会特设圆桌论坛，聚焦创新生态圈构建路径，各方代表精准建言，为产业发展支招。 临床前研究是新药研发的"第一道关口"，实验模型稀缺、平台准入门槛高等问题制约着不少企业的研发 进程。对此，良渚实验室主任欧阳宏伟表示，实验室将面向本地初创团队开放特色化实验支撑服务，旗 下大动物实验平台也将对外开放，为企业攻克研发瓶颈提供关键技术支撑。 昨天，继产业联盟宣告成立后，在随后召开的杭州市生物医药产业创新生态发展研讨会上，贝达药业 （300558）董事长丁列明分享了中国首个小分子靶向抗癌药凯美纳(盐酸埃克替尼)的研发故事："2002 年研发启动，2011年正式上市，近十年深耕终成正果。"这一故事生动诠释了本次研讨会"创新驱动"的 核心主题，来自"产学研医金"的各方代表齐聚一堂，围绕行业趋势、技术突破与生态构建展开深度对话 与思想碰撞。 中国创新药：趋势向好，机遇凸显 "疾病谱的持续变化，使现有治疗手段难以完全满足人类健康需求，这为生物医药产业带来了前所未有 的创新机遇。"浙大城市学院 ...